Anika Therapeutics ANIK Q2 2026: EPS Crushes Estimates by 1,300%
As seen on the 24/7 Wall St. homepage on July 29, 2026.
Anika Therapeutics posted adjusted EPS of $0.42, crushing the $0.03 estimate by 1300%, as gross margins expanded 14 points to 65% on manufacturing gains and record commercial channel revenue. The orthopedic regenerative medicine company raised full-year 2026 guidance and turned profitable from a year-ago loss, though expects some second-half moderation from OEM order timing.
Continue ReadingShow less
Anika Therapeutics turned in a dramatic turnaround quarter, posting adjusted EPS of $0.42 against a Wall Street estimate of just $0.03 — a beat of 1,300%. That compares with a loss in the same period a year ago, marking a meaningful inflection for a company that spent most of 2024 and the first half of 2025 reporting negative earnings. Revenue also came in well ahead of expectations at $32.61 million versus the $29.21 million estimate, a beat of nearly 12%.
The engine behind the profit surge was a 14-point expansion in gross margins, which climbed to 65%, driven by manufacturing efficiencies and record revenue through the company's commercial channel. Both of those drivers are tied to the core orthopedic regenerative medicine business, and the strength was enough for management to raise its full-year 2026 guidance.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
Investors should note that Anika flagged some expected moderation in the second half of the year, attributing it to OEM order timing rather than any deterioration in underlying demand. That caveat is worth watching as Q3 2026 results approach, particularly given that the EPS history chart shows the company has a recent track record of wide swings between reported and estimated figures.
Mentioned: ANIK